Pulse Biosciences Inc
NASDAQ:PLSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Terawulf Inc
NASDAQ:WULF
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.9), the stock would be worth $-14.61 (161% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -21.1 | $23.98 |
0%
|
| Industry Average | 12.9 | $-14.61 |
-161%
|
| Country Average | 14.4 | $-16.28 |
-168%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
1.6B USD | -21.1 | -22.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161B USD | 13.9 | 25.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160.3B USD | 45.9 | 60.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.2B USD | 20 | 39.2 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.2B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.3B USD | 19.7 | 33.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.9B EUR | 11.1 | 19.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 23.8 | 43.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 30.8 | 43.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.6B USD | 10 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.9B USD | 11.3 | 15.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Pulse Biosciences Inc
Glance View
Pulse Biosciences Inc. operates at the intriguing intersection of healthcare innovation and cutting-edge technology, focusing on the development and commercialization of their proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a novel bio-electrical platform designed to deliver ultra-short electrical pulses designed to induce cell stress and modify cell structure without significantly impacting non-cellular structural elements. The company primarily concentrates on medical applications that demand precision and safety, notably in dermatology, oncology, and other critical therapeutic areas. By developing devices like the CellFX System, Pulse Biosciences allows physicians to treat conditions with minimal invasiveness, offering alternatives to traditional methods like surgery. Pulse Biosciences generates revenue by selling these medical devices and fostering strategic partnerships within the healthcare sector to expand the application and adoption of NPS technology. The company's business model hinges on convincing healthcare professionals and institutions of the tangible benefits and potential cost savings that their innovative solutions offer. By aligning themselves with clinicians and medical researchers, Pulse Biosciences endeavors to expand the clinical indications for NPS technology, gradually scaling their market presence. Although the journey involves navigating the complex regulatory landscape and proof of clinical efficacy, the company aims to sustain growth through continuous innovation and market expansion, targeting widespread adoption of their groundbreaking platforms.
